Table 4 Effects of the combined nicotinamide riboside and nicotinamide riboside + resveratrol groups, compared to placebo, in participants with peripheral artery disease
From: Nicotinamide riboside for peripheral artery disease: the NICE randomized clinical trial
NR alone and NR + resveratrol groups combined | Placebo | Comparison of change between the combined NR groups and placebo | |||||
|---|---|---|---|---|---|---|---|
Baseline, mean (standard deviation) | Follow-up, mean (standard deviation) | Within group change, LSMeans (standard error) | Baseline, mean (SD) | Follow-up, mean (standard deviation) | Within group change, LSMeans (standard error) | LSMeans (90% CI) P value | |
6-month change in 6-min walk distance (meters) | 337.79 (90.88) N = 61 | 335.47 (93.23) N = 61 | −0.24 (5.81) | 325.60 (112.51) N = 29 | 324.58 (89.63) N = 28 | −14.29 (9.97) | +14.05 (−1.25, +∞) P = 0.12 |
3-month change in 6-min walk distance (meters) | 337.79 (90.88) N = 61 | 335.90 (90.27) N = 50 | 3.92 (5.61) | 325.60 (112.51) N = 29 | 324.03 (106.23) N = 24 | −21.34 (9.66) | +25.25 (10.43, +∞) P = 0.015 |
Maximal treadmill walking time (min) | 8.84 (4.64) N = 18 | 9.46 (3.82) N = 18 | 0.73 (0.64) | 7.14 (3.44) N = 8 | 6.13 (3.69) N = 8 | −1.33 (1.28) | +2.06 (0.24, +∞) P = 0.075 |
WIQ distance score (0-100 scale, 100-best) | 42.80 (29.96) N = 61 | 42.20 (29.82) N = 61 | −0.21 (2.94) | 42.23 (24.36) N = 28 | 48.60 (34.81) N = 28 | 6.89 (5.29) | −7.10 (−15.19, +∞) P = 0.87 |
Physical activity-total activity counts/day | 94,845 (49064) N = 53 | 90,532 (50,669) N = 53 | −1824 (4763) | 86,396 (57,208) N = 25 | 83,567 (53,856) N = 25 | −12819 (8528) | +10,995 (−2078, +∞) P = 0.14 |
Physical activity –counts per min | 471.87 (152.11) N = 53 | 455.90 (134.74) N = 53 | −9.20 (11.77) | 437.44 (116.09) N = 25 | 435.23 (124.84) N = 25 | −17.44 (20.95) | +8.24 (−23.85, +∞) P = 0.37 |
